IOVA
Iovance Biotherapeutics Inc
10.80$
+6.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
Iovance Biotherapeutics Inc (IOVA) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -302 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.1 | 0.0 | -0.6 | -6.2 | -2.2 | -3.7 | -8.6 | -18 | -33 | -79 | -101 | -159 | -205 | -228 | -293 | -362 | -353 | -302 | |
| 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 1.0 | 1.0 | 1.0 | 1.0 | 8.1 | 1.1 | 14 | 21 | 33 | 44 | 34 | |
| – | – | – | – | – | 20 | 3.8 | 8.5 | 19 | 12 | 20 | 24 | 41 | 70 | 84 | 63 | 110 | 62 | |
| – | – | – | 2.5 | -5.3 | 1.0 | 3.8 | 8.5 | 19 | 12 | 20 | 24 | 41 | 70 | 85 | – | – | – | |
| 0.0 | 0.0 | 0.0 | 0.4 | 1.5 | -0.3 | -0.5 | -0.2 | 0.4 | 0.4 | 2.7 | -2.7 | 3.0 | 25 | -2.9 | -6.5 | -123 | -24 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 1.1 | 1.5 | 1.0 | 1.2 | 6.9 | 47 | 38 | 20 | 22 | 11 | 34 | |
| – | – | – | -0.1 | 0.0 | 0.0 | -1.6 | -91 | 8.9 | 59 | -386 | 90 | -318 | 0.1 | 256 | -155 | -96 | 47 | |
| – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49 | 0.0 | – | – | – | 1.0 | – | – | – | – | |
| – | – | – | 0.9 | 0.3 | 23 | 35 | 78 | -0.6 | -1.3 | -0.2 | -0.3 | -0.3 | 1.6 | -2.6 | 2.4 | – | 1.5 | |
| – | – | – | 4.6 | – | 0.3 | – | – | – | – | 1.0 | 1.0 | 1.0 | 1.0 | 0.0 | 0.0 | – | – | |
| – | 0.0 | 1.9 | 5.5 | 1.7 | 23 | 35 | 78 | 97 | 59 | 424 | 6.1 | 576 | 239 | 190 | 463 | 391 | 301 | |
| -0.1 | 0.0 | 1.3 | -0.8 | -0.5 | 20 | 25 | -31 | 73 | 39 | -63 | -63 | 53 | 11 | 154 | -57 | -59 | 47 | |
| -0.1 | 0.0 | -0.6 | -6.2 | -2.2 | -3.7 | -10 | -20 | -34 | -80 | -102 | -166 | -252 | -266 | -313 | -384 | -364 | -336 |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.